StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN)

StockNews.com started coverage on shares of Oragenics (NYSE:OGENGet Rating) in a report published on Monday. The firm issued a hold rating on the stock.

Oragenics Trading Up 2.7 %

Shares of NYSE OGEN opened at $0.20 on Monday. Oragenics has a 12 month low of $0.18 and a 12 month high of $0.63. The firm has a market capitalization of $22.89 million, a PE ratio of -1.50 and a beta of 0.24. The firm has a fifty day simple moving average of $0.22 and a two-hundred day simple moving average of $0.29.

Oragenics Company Profile

(Get Rating)

Oragenics, Inc develops antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus; and Terra CoV-2, an intramuscular vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.

Further Reading

Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.